Loading people...
Amit Shah is a Principal at SR One, a leading venture capital firm focused on the life sciences sector. He is involved in identifying, evaluating, and supporting innovative biotechnology and healthcare companies.
Amit Shah invests in a wide range of life sciences companies, including those in biotechnology, novel therapeutics, drug discovery platforms, medical devices, and digital health solutions. His focus is on innovations that address significant unmet medical needs.
Amit Shah works as a Principal at SR One, a prominent venture capital firm dedicated to investing in the life sciences industry.
Amit Shah is a Principal at SR One, a prominent trans-Atlantic life sciences venture capital firm based in London, UK, that has successfully invested in over 500 companies. He holds a BA in Medical Sciences, an MA in Neuroscience, and an MD from the University of Cambridge, and previously practiced as a board-certified equivalent plastic surgeon specializing in microsurgical cancer reconstruction. Before joining SR One in early 2018, Shah held multiple strategic roles at GlaxoSmithKline, where he focused on late-phase clinical development, global medical affairs, and early pipeline commercial strategy. Additionally, since 2020, he has served on the venture capital panel for the BioInnovation Institute, an international life sciences incubator backed by Novo Nordisk. His current professional focus centers on identifying, funding, and scaling early-stage biotechnology and therapeutics companies to advance modern healthcare innovations globally.
Amit Shah is a distinguished Principal at SR One, a prominent venture capital firm dedicated to investing in the future of life sciences. In his role, Amit is instrumental in sourcing, evaluating, and executing investments in early stage and growth stage companies that are at the forefront of scientific innovation. His work at SR One contributes to the firm's mission of partnering with visionary entrepreneurs to develop transformative medicines and healthcare solutions.
SR One is renowned for its deep expertise in the life sciences, and Amit Shah's investment focus aligns perfectly with this specialization. He is particularly interested in biotechnology, novel therapeutics, drug discovery platforms, medical devices, and digital health solutions that promise to significantly improve patient outcomes. Amit actively seeks out companies with strong scientific foundations, compelling intellectual property, and experienced management teams capable of bringing their innovations to market. His strategic insights help guide portfolio companies through critical development milestones, from preclinical research to clinical trials and commercialization.
While specific details of Amit Shah's career background are not publicly detailed, individuals in his position at a leading life sciences VC firm typically possess a robust blend of scientific acumen, industry experience, and financial expertise. It is common for Principals at SR One to have backgrounds in scientific research, medicine, pharmaceutical development, or prior roles in venture capital or corporate development within the healthcare sector. This diverse experience allows them to thoroughly assess complex scientific data, understand market dynamics, and identify high-potential investment opportunities. Amit's contributions are vital in navigating the intricate landscape of life sciences investment, ensuring SR One continues to support companies poised for significant impact.
SR One has a long history of backing successful ventures, and Amit Shah's efforts contribute to this legacy by identifying the next generation of life sciences leaders. His work involves extensive due diligence, market analysis, and building strong relationships with founders and scientific advisors. Through his strategic involvement, Amit helps shape the trajectory of innovative companies, fostering their growth and ultimately bringing new therapies and technologies to patients worldwide. His dedication underscores SR One's commitment to advancing healthcare through strategic capital and expert guidance.
